Medplus Health Services Earnings Call Transcript: Key Takeaways
Medplus reported Q2 revenue of ₹2,037.1 Cr with 21.3% pharmacy growth, but EBITDA margins were hit by state-mandated wage hikes.
- Call
- Guides 10% growth
ALFA Filings
Every announcement, straight from the exchange
Every earnings call announcement on NSE and BSE that our alert engine sent, newest first. Each one has its own page with the summary, the key figures and the original filing.
Time
9,412 announcements
Medplus reported Q2 revenue of ₹2,037.1 Cr with 21.3% pharmacy growth, but EBITDA margins were hit by state-mandated wage hikes.
ABD achieved record quarterly volumes crossing 10 million cases, driven by aggressive premiumization and the turnaround of flagship brands in key Southern markets.
Q2 FY27 revenue $5,145mn, +1.5% YoY cc; op margin 21%; FCF $928mn; AI 10.5% of revenue. FY27 revenue guidance cut to 1–2% cc from 1.5–3%.
Q2 FY27 revenue ₹347.68 cr (+90% YoY), EBITDA ₹72.92 cr, PAT ₹33.68 cr. Volume-led growth; debt/EBITDA improved to 2.09x in H1 FY27.
Q2 FY27 constant-currency revenue grew 1.5% YoY, below plan, and FY27 guidance was cut to 1-2% from 1.5-3%. Operating margin held at 21%; AI revenue reached 10.5% of sales, up 29% QoQ.
Q2 FY27 revenue ₹426.73M (+25% QoQ), EBITDA ₹119.56M at 28.0% margin, PAT ₹85.47M (+14% QoQ). Strategy centres on IPO-funded capacity expansion in forging and machining.
Q2FY27 PAT ₹4,183mn (+77% YoY), NII ₹8,125mn (+69%), AUM ₹438,785mn (+62%). Cost-income improved to 41.4%. No explicit numeric guidance.
Revenue growth was driven by new products, though margins were temporarily impacted by non-recurring security costs and bonuses.
Hyundai recorded its highest-ever quarterly revenue but faced significant margin pressure from steep raw material inflation and competitive intensity.
Q2 FY27 revenue ₹14,162 Mn (+6.6% YoY, +2.7% QoQ; USD CC -1.1% YoY), EBITDA margin 15.2%, PAT ₹1,596 Mn (+37.5% YoY). Interim dividend ₹3.00/share.
Q2 FY27: PAT INR 617 cr (+6% YoY), loan book INR 95,079 cr (+19% YoY), NIM 3.67%, GNPA 0.91%. Strategy shifts toward high-yield Affordable and Emerging Markets segments.
Raymond delivers 21% revenue growth driven by a massive 72% jump in Aerospace, though engineering margins remain under pressure from high R&D expensing.
PFS returns to growth after 10 quarters of contraction, hitting multi-year highs in sanctions.
Vedanta delivered record revenue and EBITDA driven by operational execution and cost management post-demerger.
Revenue grew 22% YoY, but EBITDA fell 22% due to soaring energy costs and lower agri margins.
Solid growth in AUM and profitability driven by two-wheeler demand and geographical expansion.
Arvind delivered record revenue and EBITDA despite geopolitical disruption. Advanced Materials is becoming a primary engine, diversifying the earnings portfolio away from cyclical textiles.
Q2 FY27 standalone: NII Rs 8,728Mn (+31%), PAT Rs 4,159Mn (+27%), NIM 3.87%, GNPA 1.44%. Deposits +21%, advances +26% YoY. Gold loans ~30% of advances.
Quick Heal is pivoting from a declining B2C antivirus market to Enterprise cybersecurity (Seqrite), showing early signs of recovery.
Revenue grew 37% but PAT fell 17% as raw material volatility and energy costs severely squeezed margins.
Revenue grew 25% YoY driven by API demand, but gross margins contracted 400bps due to rising solvent costs and geopolitical disruptions.
Q2FY27 consolidated PAT ₹176 Cr (+231% YoY); H1FY27 standalone PAT ₹292 Cr (+209%). Consolidated AUM ₹16,589 Cr (+31%). Asset quality and credit cost improving.
Q2FY27: PAT ₹6.2bn (+23.9% QoQ), NII ₹29.6bn (+14.4% YoY), operating profit ₹15.6bn (+18.8% YoY), NIM 6.1%, GNPA 3.1%. Secured mix rose to 57.3%.
Gravita delivered resilient H1 growth despite geopolitical scrap sourcing headwinds. Management pivots to higher-margin copper recycling and US expansion to mitigate supply chain disruptions.
Waaree delivers robust H1 growth driven by retail momentum, but rationalizing 3GW of US orders reveals geopolitical vulnerability. Management is aggressively pivoting to backward integration and BESS to mitigate module price volatility.
Q2 FY27 consol revenue +22% to INR2,484cr; EBITDA +24% to INR706cr (28.4%, +50bps); PAT +23% to INR349cr. FY27 revenue growth guidance raised to 15-17%.
Q2 FY27 record revenue of ₹20,696 Cr (+18.5% YoY) and record 219,072 units (+14.7%). PAT fell 23.9% to ₹1,196 Cr on raw-material cost inflation.
Q2 FY27 revenue ₹22,066 Cr (+41% YoY), EBITDA ₹10,192 Cr (+83% YoY), PAT ₹6,187 Cr (+105% YoY); record 649 KT aluminium output.
Indus Towers delivered steady operational growth driven by strong co-location additions and network expansion from a major customer.
Q2 FY27 revenue Rs1,123 Cr (+1.5% YoY); EBIT Rs50 Cr (4.4% margin vs 3.0%); PAT Rs26 Cr vs Rs10 Cr. Consumer Products grew while Lighting declined.